GENERAL COMMENTS
The abstract should state that the results were not statistically significant, but this is likely to be due to the trial being of inadequate size.
This is a well conducted trial on a clinically relevant topic and deserves publication. The trial suffered from slow recruitment, and so is unable to present results that are statistically significant, although the results do appear to be clinically relevant and have the potential to change clinical practice. The major unanswered question is why the infection rate in the control group was so high, and this impacts on the generalisability of the findings. The authors adequately address this question in this paper, but it does require further investigation.
The study would be an excellent pilot for a more definitive trial with external funding. 
REVIEWER

GENERAL COMMENTS
Overall I found this to be a well written and clear manuscript, reporting a placebo controlled RCT testing the effects of antibiotic prophylaxis after excision of lower limb skin lesions. Although well reported, I had immediate concerns about the likely usefulness of such a study on the basis of the abstract alone that indicated that only 52 patients were recruited into the study with the aim of comparing surgical site infection (SSI) between groups. Experience suggests, even before reading the justification for the sample size, that this is likely to be an inadequate number of study participants from which to draw any meaningful conclusions. The sample size calculation is correct and reasonable in my view, and suggests that in the order of 280+ participants would be required to obtain a definitive view on treatment efficacy. However, the authors report that due to reasons of poor recruitment and time constraints the study was terminated after recruiting only 52 participants on the basis that the risk difference between interventions was at the 10% absolute risk difference level that they had hypothesized as being clinically significant before commencement of the study. This latter strategy is plainly a nonsensical explanation for stopping a trial. If we reverse the argument and say if a study was recruiting well and was likely to reach the sample size target within the allowed time, would anyone really consider stopping a study for futility if the treatment effect were marginally less than the expected 10% risk reduction? No. Certainly no study Data Monitoring Committee would ever suggest such a thing. So why would we infer differences between treatments based on only 3 and 10 infections in the groups? I am afraid we can conclude nothing useful about treatment efficacy from this study. Using a more formal statistical argument, by selectively deciding to stop a study at a time when the estimated treatment effect reaches some threshold we will always inflate the type I error (that is, we will increase our chances of incorrectly rejecting a true null hypothesis); so the conclusions the authors make about rejection at the 5% level for the per-protocol analysis are unlikely to be valid. Maybe the observed differences in the SSI rates between groups were due to the imbalances in the baseline data that the authors report; again a not untypical consequence of such a small study. Why do the authors not attempt to adjust for the baseline imbalance in the analysis? Why not try multiple logistic regression? The authors are right also to be concerned about the consistency of GP training and potential confounding effects of "GP" specific clustering effects; that is the particularly good or bad practice of one or more GPs confounding the treatment effect. The authors should provide a more informative breakdown of the number of procedures undertaken by each GP and the split between treatment groups. Most often stratification by surgeon, GP or therapist is recommended when randomizing where these issues may be important. The authors should consider this for future RCTs.
In conclusion, this is a well written manuscript, but it reports a study that we can simply conclude little or nothing from regarding treatment efficacy. My advice to the authors would be to re-write this as a pilot/feasibility study, as it seems to me that it provides very useful data and knowledge for planning a larger (definitive) study.
VERSION 1 -AUTHOR RESPONSE
In response to Parson's comments we have altered the discussion to emphasize that the trial did not identify a statistical significant reduction and was underpowered and therefore no conclusions on the efficacy of this intervention can be drawn. For the sake of completeness of reporting we have left both the intention-to-treat analysis and per-protocol analysis in the results section. If it is felt that this is still too confusing and may appear misleading the per-protocol analysis can be removed.
We appreciate Parson's suggestions regarding multiple logistic regression to adjust for the baseline differences between the groups. Given the trial was underpowered and did not identify any statistically significant relationship we have foregone this additional analysis at this time as it will not affect the outcome of the trial or its interpretation. If it is still felt that this analysis is integral it can be incorporated into the manuscript.
We have also not incorporated any cluster analysis to adjust for differences in GP outcomes. Firstly as we feel it does not affect the outcome of the trial or its interpretation, given the lack of a statistically significant finding. Secondly as Mackay is a small community and the anonymity and confidentiality of the doctors involved has been guaranteed in order for their involvement.
